Cystatin C: How to Interpret Your Result

By
Published Updated Last reviewed
Medical lab testing image for Cystatin C: How to Interpret Your Result

At a glance

  • Normal adult range / 0.62 to 1.15 mg/L (most laboratory reference intervals)
  • High result means / reduced glomerular filtration rate (GFR), possible CKD
  • Low result means / usually not clinically concerning; may reflect low muscle or thyroid activity
  • Best use / eGFR calculation when creatinine is unreliable (low muscle mass, amputation, high-protein diet)
  • Gold-standard formula / CKD-EPI Cystatin C 2021 equation
  • Typical units / mg/L (some labs report mg/dL; multiply by 10 to convert)
  • Confounders that raise cystatin C / corticosteroids, hyperthyroidism, high CRP
  • Confounders that lower cystatin C / hypothyroidism, low corticosteroid state
  • Requires fasting / No
  • Turnaround time / 1 to 3 business days at most reference labs

What Cystatin C Actually Measures

Cystatin C is a cysteine-protease inhibitor produced at a near-constant rate by every nucleated cell in the body. Because its production rate does not depend on muscle mass, sex, or diet, it behaves as a more consistent filtration marker than creatinine. The kidneys filter it freely at the glomerulus, and virtually none is secreted or reabsorbed by tubular cells, making the serum level a direct reflection of glomerular filtration rate (GFR). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD formally endorsed cystatin C as a confirmatory GFR marker in 2012.

Why Creatinine Alone Can Miss Kidney Decline

Creatinine production depends heavily on muscle mass. A 45-year-old bodybuilder and a 78-year-old woman with sarcopenia may have identical serum creatinine of 0.9 mg/dL while their true GFRs differ by 30 mL/min/1.73 m². A 2012 NEJM study (N=3,418) found that reclassifying CKD stage with cystatin C rather than creatinine alone changed the prognosis category for roughly 24% of participants previously labeled CKD stage 3 by creatinine. That paper concluded: "Cystatin C provides a more accurate estimate of GFR than creatinine in persons with reduced muscle mass."

The CKD-EPI 2021 Equation

The 2021 update to the CKD-EPI equation replaced older race-based coefficients and validated separate Cystatin C and combined creatinine-cystatin C formulas. According to the CKD-EPI 2021 publication in NEJM (Inker et al., N=12 cohorts), the combined creatinine-cystatin C equation had the lowest bias and highest precision of any single-marker formula. Using both markers together reduces misclassification of GFR by approximately 20% compared with creatinine alone. Most major electronic health record systems now auto-calculate eGFRcr-cys when both values are ordered simultaneously.

Normal Cystatin C Range by Age and Population

The most commonly cited adult reference interval is 0.62 to 1.15 mg/L, derived from studies of healthy adults with measured GFR above 60 mL/min/1.73 m². Reference ranges vary slightly by laboratory platform.

Age-Related Changes

GFR declines roughly 1 mL/min/1.73 m² per year after age 40 in otherwise healthy adults, so cystatin C rises gradually with age even without kidney disease. A 2017 analysis from the Chronic Renal Insufficiency Cohort (CRIC) study found median cystatin C of 0.84 mg/L in participants aged 21 to 40 versus 1.08 mg/L in those aged 61 to 74 with no diagnosed kidney disease. That age effect does not mean older adults should accept borderline-high values without evaluation. It means clinical context determines next steps.

Pediatric Reference Ranges

Children have lower cystatin C than adults. Newborns start above 1.5 mg/L because of immature renal function, and values fall to adult reference range by approximately age 2. The KDOQI Pediatric CKD guideline update recommends using age-specific reference intervals and the Schwartz bedside equation adapted for cystatin C when evaluating children under 18.

Sex Differences

Sex differences in cystatin C are small compared with creatinine. A cross-sectional analysis published in AJKD (Rule et al., N=580) showed men averaged 0.06 mg/L higher than women after adjusting for measured GFR, a gap narrow enough that most labs use a single adult reference interval for both sexes.

How to Interpret a High Cystatin C Result

A value above 1.15 mg/L in an adult suggests GFR may be below 60 mL/min/1.73 m², the threshold for CKD diagnosis. A single elevated result does not confirm CKD. KDIGO requires two measurements at least 90 days apart before assigning a CKD stage. See KDIGO 2012, Chapter 1.

Grading Severity

| Cystatin C (mg/L) | Approximate eGFRcys (mL/min/1.73 m²) | KDIGO G Stage | |---|---|---| | 0.62 to 1.15 | 60 to 120+ | G1, G2 (normal to mildly reduced) | | 1.16 to 1.50 | 45 to 59 | G3a (mildly to moderately reduced) | | 1.51 to 2.00 | 30 to 44 | G3b (moderately to severely reduced) | | 2.01 to 3.00 | 15 to 29 | G4 (severely reduced) | | Above 3.00 | Below 15 | G5 (kidney failure) |

Values are approximations using CKD-EPI Cystatin C 2021. Individual results must be entered into the validated calculator at niddk.nih.gov for precise staging.

Non-Renal Factors That Raise Cystatin C

Cystatin C is not purely a kidney marker. Certain conditions raise it independently of GFR. Chronic corticosteroid use increases cystatin C production by approximately 11 to 15% at prednisone doses above 20 mg/day, according to a controlled study in Clinical Chemistry (Risch et al.). Hyperthyroidism, high C-reactive protein (a proxy for systemic inflammation), and higher body fat percentage may each nudge cystatin C upward. Any provider interpreting an elevated result should rule out these confounders before diagnosing CKD.

When a High Result Needs Urgent Attention

An eGFRcys below 15 mL/min/1.73 m², corresponding to cystatin C generally above 3.0 mg/L, warrants same-week nephrology referral. According to KDIGO 2022 CKD Management guidelines, patients in G5 should be evaluated for kidney replacement therapy initiation. A rapid rise of more than 0.3 mg/L over 48 to 72 hours is consistent with acute kidney injury and requires urgent clinical evaluation.

How to Interpret a Low Cystatin C Result

A result below 0.62 mg/L is uncommon and rarely a primary clinical concern. Low cystatin C does not indicate abnormally high kidney clearance in most contexts. Several conditions are associated with low values.

Causes of Low Cystatin C

Hypothyroidism suppresses cystatin C production. A prospective study in NDT (Fricker et al., N=96) documented mean cystatin C of 0.54 mg/L in hypothyroid patients versus 0.78 mg/L after euthyroid state was restored with levothyroxine. Adrenal insufficiency and very low corticosteroid levels may also reduce cystatin C. Neither represents a kidney problem. They represent reduced production of the protein, not elevated clearance.

Is a Low Result Ever Concerning?

Low cystatin C combined with low creatinine and low BUN in a thin or malnourished patient may signal protein-calorie malnutrition rather than excellent kidney health. The NKF/ASN Task Force 2021 report on GFR estimation notes that cystatin C can be falsely reassuring in severe muscle-wasting states when GFR is actually reduced. Clinical correlation with urinalysis, urine albumin-to-creatinine ratio, and blood pressure is always warranted.

Cystatin C vs. Creatinine: When to Order Each

Both markers estimate GFR, but each has a different error profile. The decision framework below helps identify which test (or combination) serves each patient best.

Order Cystatin C When Creatinine Is Unreliable

  • Sarcopenia or low muscle mass. Athletes, elderly adults, and patients with neuromuscular disease all produce abnormal amounts of creatinine, making creatinine-based eGFR inaccurate.
  • Amputation. Loss of a limb reduces creatinine production dramatically. Cystatin C is unaffected.
  • Liver disease. Reduced hepatic creatine synthesis lowers creatinine independent of GFR.
  • Pregnancy. GFR rises 40 to 60% during pregnancy, but creatinine values may appear deceptively normal. A review in AJKD (Hladunewich et al.) identifies cystatin C as a more sensitive marker of GFR changes in the second and third trimesters.
  • Confirming G3 CKD. KDIGO 2012 explicitly recommends adding cystatin C to confirm or reclassify CKD stage in anyone with eGFRcr between 45 and 59 mL/min/1.73 m² who has no albuminuria or other kidney damage markers. See Recommendation 1.4.3.

When Creatinine Alone May Be Sufficient

For healthy adults under 50 with no metabolic disease, normal muscle mass, and no medications known to affect GFR markers, a standard metabolic panel with creatinine-based eGFR is adequate for initial screening. Cystatin C adds incremental value proportional to the clinical pre-test probability of discordance.

The Combined Equation Advantage

When both creatinine and cystatin C are available, the CKD-EPI 2021 creatinine-cystatin C equation (eGFRcr-cys) outperforms either marker alone. Inker et al. Demonstrated a root mean square error of 17.0 mL/min/1.73 m² for creatinine alone versus 13.7 mL/min/1.73 m² for the combined equation across 12 external validation cohorts, published in NEJM 2021. The combined test costs roughly $15 to 25 more than creatinine alone at most reference labs.

How Cystatin C Connects to Cardiovascular Risk

Kidney function and cardiovascular health are tightly linked. Cystatin C adds prognostic information beyond standard lipid panels and blood pressure. A prospective analysis from the MESA study (N=6,814) found that each 0.1 mg/L increase in cystatin C was associated with a 10% increase in risk of cardiovascular events after adjusting for traditional Framingham risk factors. The American Heart Association 2021 scientific statement on kidney-heart interactions recommends cystatin C as part of the cardiorenal risk assessment panel for patients with GFR in the G3 range.

Metabolic Syndrome and Insulin Resistance

Insulin resistance raises cystatin C modestly even before frank CKD develops. A cross-sectional study from the NHANES III dataset found cystatin C was significantly higher in adults with metabolic syndrome (mean 1.04 mg/L) compared with metabolically healthy controls (mean 0.88 mg/L), P<0.001, after adjusting for age and sex. Addressing insulin resistance through weight reduction, physical activity, and appropriate pharmacotherapy may slow cystatin C rise over time, though no randomized controlled trial has used cystatin C change as a primary endpoint to date.

Factors That Can Lower a High Cystatin C

No medication directly reduces cystatin C production in patients with true kidney disease. The only reliable way to lower an elevated result is to improve GFR or remove the non-renal confounder raising it.

Blood Pressure Control

Tight blood pressure management slows GFR decline in CKD. The SPRINT trial (N=9,361) showed that systolic blood pressure targets below 120 mmHg reduced the composite cardiovascular outcome by 25% and slowed kidney function deterioration in participants with baseline eGFR as low as 20 mL/min/1.73 m², published in NEJM 2015.

RAAS Blockade

ACE inhibitors and angiotensin receptor blockers reduce intraglomerular pressure and proteinuria in CKD. The IDNT trial (N=1,715) demonstrated that irbesartan 300 mg daily reduced the primary composite renal endpoint by 20% versus amlodipine in patients with type 2 diabetes and nephropathy. Cystatin C may rise slightly in the first 4 to 8 weeks of RAAS therapy due to reduced intraglomerular pressure. A stable or mildly elevated cystatin C in the setting of RAAS initiation does not necessarily signal worsening kidney disease.

SGLT2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) reduce intraglomerular pressure via tubuloglomerular feedback. The DAPA-CKD trial (N=4,304) showed dapagliflozin 10 mg daily reduced the composite of sustained 50% decline in eGFR, end-stage kidney disease, or kidney/cardiovascular death by 39% versus placebo, published in NEJM 2020. Like RAAS blockers, SGLT2 inhibitors cause an acute functional GFR dip in the first 2 to 4 weeks that transiently raises creatinine and possibly cystatin C before the long-term protective effect stabilizes.

Eliminating Non-Renal Confounders

If cystatin C is elevated primarily because of corticosteroid use or hyperthyroidism, treating the underlying condition returns cystatin C toward baseline without any direct kidney intervention. Tapering prednisone from 40 mg to physiologic doses (<7.5 mg/day) may reduce cystatin C by 0.10 to 0.20 mg/L in patients with normal underlying GFR. Always recheck cystatin C 4 to 6 weeks after a major change in corticosteroid dose before drawing conclusions about kidney function trends.

What to Do With Your Result: A Practical Path Forward

Normal result (0.62 to 1.15 mg/L) in a low-risk adult: no immediate action needed. Recheck in 12 months as part of routine metabolic screening if any CKD risk factors are present (diabetes, hypertension, family history of kidney disease, obesity).

Mildly elevated result (1.16 to 1.50 mg/L): confirm with a repeat test at least 90 days later per KDIGO criteria. Add urine albumin-to-creatinine ratio (UACR) and renal ultrasound if creatinine-based eGFR also falls below 60 mL/min/1.73 m². Check for non-renal confounders (TSH, CRP, current steroid dose).

Moderately to severely elevated result (above 1.50 mg/L): nephrology referral is appropriate. Optimize blood pressure to a target below 130/80 mmHg per AHA/ACC 2017 hypertension guidelines. Initiate RAAS blockade if albuminuria is present. Discuss SGLT2 inhibitor eligibility.

Very high result (above 3.0 mg/L): same-week nephrology evaluation. Prepare for discussion of kidney replacement therapy modality planning.

Frequently asked questions

›What is a normal Cystatin C level?
For most adults, the reference interval is 0.62 to 1.15 mg/L. Values vary slightly by laboratory platform. Children under 2 and adults over 70 may have slightly different expected ranges due to immature or age-related decline in kidney function respectively. Always compare your result against your specific lab's reference range printed on the report.
›What does a high Cystatin C mean?
A result above 1.15 mg/L suggests the kidneys are filtering less efficiently than normal. It corresponds to a lower estimated GFR. Causes include chronic kidney disease, acute kidney injury, uncontrolled diabetes, hypertension, and non-renal factors like corticosteroid use or hyperthyroidism. A single high result is not diagnostic on its own. KDIGO guidelines require two elevated readings at least 90 days apart to diagnose CKD.
›What does a low Cystatin C mean?
A result below 0.62 mg/L is uncommon and usually not a kidney problem. Hypothyroidism is the most recognized cause of low cystatin C because thyroid hormones regulate its production. Adrenal insufficiency may also lower values. Low cystatin C does not indicate dangerously high kidney clearance in most clinical scenarios. Thyroid function testing (TSH) is a reasonable first step when cystatin C is unexpectedly low.
›Is Cystatin C more accurate than creatinine?
For most populations, yes, especially when muscle mass is abnormal. The CKD-EPI 2021 combined creatinine-cystatin C equation has lower bias and higher precision than creatinine alone across 12 external validation cohorts (Inker et al., NEJM 2021). For healthy adults with normal muscle mass, the difference between the two markers is small, but in elderly patients, people with sarcopenia, or anyone who has had an amputation, cystatin C provides substantially more reliable GFR estimates.
›Do I need to fast before a Cystatin C test?
No fasting is required. Cystatin C production is not affected by recent meals, unlike triglycerides or glucose. You can have the blood draw at any time of day.
›Can exercise raise Cystatin C?
Acute intense exercise transiently raises serum creatinine more than cystatin C. Some studies suggest prolonged strenuous exercise may modestly raise cystatin C for 24 to 48 hours post-exertion, but the effect is small and not clinically significant for routine monitoring. Avoid intense exercise within 24 hours of a scheduled draw if you want the most stable baseline.
›How often should I recheck Cystatin C?
The answer depends on your CKD stage and risk factors. For confirmed CKD G3a, KDIGO recommends monitoring kidney function at minimum once per year. For G3b, twice yearly. For G4, three to four times per year. People with no known kidney disease but risk factors such as diabetes or hypertension should check cystatin C or creatinine-based eGFR at least annually.
›Can diet change my Cystatin C result?
Diet has a smaller effect on cystatin C than on creatinine. Eating a very high-protein meal before a creatinine test inflates the result, but cystatin C is largely unaffected. However, long-term dietary patterns that reduce inflammation and blood pressure, like the DASH diet, may slow the GFR decline that drives cystatin C upward over years.
›Does metformin affect Cystatin C?
Metformin itself does not directly alter cystatin C production. However, metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and requires dose review when eGFR falls below 45 mL/min/1.73 m² per FDA labeling. A rising cystatin C that pushes eGFRcys into those ranges should trigger a medication review with your prescriber.
›Should I use an online calculator to convert my Cystatin C to eGFR?
Yes. Enter your cystatin C value (and creatinine if available) into the NIDDK-validated CKD-EPI 2021 calculator at niddk.nih.gov. The raw mg/L number alone does not tell you your GFR stage. The calculated eGFRcys places you in a KDIGO G stage that guides monitoring frequency and treatment decisions.
›Can cystatin C detect early kidney disease before symptoms appear?
Yes. GFR can fall to around 60 mL/min/1.73 m² before any symptoms develop, and cystatin C rises into the abnormal range at that point. For patients with diabetes or hypertension, cystatin C may identify mild GFR reduction years before creatinine crosses the lab reference range upper limit, providing a longer window for intervention.

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150.
  2. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305(15):1545-1552.
  3. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749.
  4. Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932-943.
  5. Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006;69(2):399-405.
  6. Fricker M, Wiesli P, Brändle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63(5):1944-1947.
  7. Risch L, Herklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001;47(11):2055-2059.
  8. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142(7):497-505.
  9. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
  10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
  11. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446.
  12. Hladunewich M, Hercz AE, Keunen J, et al. Cystatin C in pregnancy. Am J Kidney Dis. 2008;51(3):485-492.
  13. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Brodehl J. Cystatin C reference values in pediatric patients. Pediatr Nephrol. 1998;12(2):125-129.
  14. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3):167-174.
  15. NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021;32(12):2994-3015.
  16. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127.
  17. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.
  18. American Heart Association. Kidney-heart connections: a scientific statement from the AHA. Circulation. 2021;143(14):e765.